Aandelen in “Medische Specialiteiten”

Aandeel Datum Koers Evolutie
vlag Repro-Med Systems, Inc. 13/02 4,670 USD
+6,86% 		+6,86%
vlag Resmed Inc. 13/02 252,550 USD
+2,78% 		+2,78%
vlag Retractable Technologies Inc 13/02 0,661 USD
-0,90% 		-0,90%
vlag Rockwell Medical Inc 13/02 1,010 USD
-0,98% 		-0,98%
vlag RUA Life Sciences Plc 13/02 14,250 GBX
0,00% 		0,00%

Nieuws over “Medische Specialiteiten”

14/02 · Inspire Medical Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inspire Medical Systems, Inc. - INSP · Persbericht

14/02 · Inspire Medical Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inspire Medical Systems, Inc. - INSP · Persbericht

13/02 · Boston Scientific to participate in TD Cowen's 46th Annual Health Care Conference · Persbericht

13/02 · Medtronic receives FDA clearance for Stealth AXiS™ surgical system, first integrated planning, navigation and robotics platform for spine surgery · Persbericht

13/02 · EssilorLuxottica announces the launch of a share buyback program · Persbericht

12/02 · Artivion Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

12/02 · Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO · Persbericht

12/02 · INOVIO to Participate in Upcoming Scientific and Investor Conferences · Persbericht

12/02 · BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market · Persbericht

12/02 · West Reports Fourth-Quarter and Full-Year 2025 Results · Persbericht

11/02 · QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results · Persbericht

11/02 · Medtronic to announce financial results for its third quarter of fiscal year 2026 · Persbericht

11/02 · EssilorLuxottica: EssilorLuxottica Board of Directors Proposes Renewal of Eight Directors · Persbericht

11/02 · EssilorLuxottica: Q4/FY 2025 Results - Revenue growing 18.4% in Q4 and 11.2% in the FY. Adj. operating margin at 16.0% in the FY · Persbericht

11/02 · Coloplast A/S - Updated Financial Calendar 2025-26 · Persbericht

11/02 · INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 · Persbericht

11/02 · Stryker launches T2 Alpha Humerus Nailing System, supporting surgical workflow and care for complex fractures · Persbericht

11/02 · Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook · Persbericht

11/02 · SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments · Persbericht

11/02 · AI-vrees slaat over naar financials · LYNX

Beursnieuws Amerika De Amerikaanse aandelenmarkten deden dinsdag een stapje terug, na eerdere winsten op maandag. Beleggers hadden aandacht voor macro-economische onzekerheden en de toenemende impact van kunstmatige intelligentie...

10/02 · TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 · Persbericht

Mijn selecties